Status:
COMPLETED
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
Lead Sponsor:
Merrimack Pharmaceuticals
Collaborating Sponsors:
Sanofi
Conditions:
Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
To evaluate the safety and tolerability of escalating doses of MM-121 + certain anticancer therapies
Detailed Description
This study was a Phase 1 and pharmacologic dose-escalation trial of MM-121 in combination with certain anticancer therapies. The dose-escalation portion of the study employed a 3 + 3 design to assess ...
Eligibility Criteria
Inclusion
- Advanced-stage solid tumors
- ≥ 18 years of age
- Adequate liver and kidney function
Exclusion
- Any other active malignancy
- No known HIV, Hepatitis C or B
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT01447225
Start Date
October 1 2011
End Date
January 1 2014
Last Update
September 14 2016
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Lafayette, Indiana, United States, 47905
2
Buffalo, New York, United States, 14263
3
Cincinnati, Ohio, United States, 45267
4
Philadelphia, Pennsylvania, United States, 19111